Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 4/20 | 0.78 |
| ▸ | PARP1 | P09874 | 2/20 | 0.61 |
| ▸ | KIF11 | P52732 | 1/20 | 0.58 |
| ▸ | CHUK | O15111 | 4/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | GABRP | O00591 | 1/20 | 0.58 |
| ▸ | GABRD | O14764 | 1/20 | 0.58 |
| ▸ | IKBKB | O14920 | 1/20 | 0.58 |
| ▸ | AURKA | O14965 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | PIM1 | P11309 | 1/20 | 0.58 |
| ▸ | TOP1 | P11387 | 1/20 | 0.58 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.58 |
| ▸ | IDO1 | P14902 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.58 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.58 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29642993 | 1.00 | ACHE (0.78) | ACHEPARP1KIF11CHUKKDM4E | |
| SCHEMBL29478498 | 0.91 | CHUK (0.73) | ACHEPARP1KIF11CHUKKDM4E | |
| SCHEMBL12590220 | 0.91 | CHUK (0.73) | ACHEPARP1KIF11CHUKKDM4E | |
| SCHEMBL121401 | 0.89 | ACHE (1.00) | ACHEPARP1KIF11CHUKKDM4E | |
| SCHEMBL29382084 | 0.89 | ACHE (1.00) | ACHEPARP1KIF11CHUKKDM4E | |
| Hydrochloric Acid SCHEMBL4436954 | 0.87 | ACHE (0.96) | ACHEPARP1KIF11CHUKKDM4E | |
| Water SCHEMBL2197266 | 0.87 | ACHE (0.96) | ACHEPARP1KIF11CHUKKDM4E | |
| Hydrochloric Acid SCHEMBL3234011 | 0.87 | ACHE (0.96) | ACHEPARP1KIF11CHUKKDM4E | |
| SCHEMBL12396546 | 0.85 | ACHE (0.61) | ACHEPARP1KIF11CHUKKDM4E | |
| SCHEMBL12166058 | 0.82 | CHUK (0.77) | ACHEPARP1KIF11CHUKGABRP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 119 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102276514-B | Fluorene-bridged blue phosphorescent main body material and preparation method and application thereof | UNIV HUAZHONG SCIENCE TECH | 2014-01-15 | — | — | CN | claimed |
| CN-102276514-A | Fluorene-bridged blue phosphorescent main body material and preparation method and application thereof | — | 2011-12-14 | — | — | CN | claimed |
| EP-1910379-B1 | CASPASE INHIBITOR PRODRUGS | VERTEX PHARMA (US) | 2011-10-19 | — | — | EP | claimed |
| US-20110144074-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-06-16 | — | — | US | claimed |
| US-7879891-B2 | such as (S)-Carbazole-9-carboxylic acid 1-(3a-fluoromethyl-5-oxo-3a,5,6,6a-tetrahydro-furo[3,2-d]oxazol-2-yl)-2-methyl-propyl ester, used for the treatment of diseases related to inflammatory or degenerative conditions | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-02-01 | — | — | US | claimed |
| US-20090215736-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2009-08-27 | — | — | US | claimed |
| US-7442790-B2 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 2008-10-28 | — | — | US | claimed |
| EP-1923386-A2 | Carbamate caspase inhibitors and uses thereof | Vertex Pharmceuticals Incorporated (US) | 2008-05-21 | — | — | EP | claimed |
| EP-1268425-B1 | CARBAMATE CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMA (US) | 2008-01-23 | — | — | EP | claimed |
| US-20080015172-A1 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | claimed |
| US-20070155718-A1 | Caspase inhibitor prodrugs | VERTEX PHARMACEUTICALS INCORPORATED | 2007-07-05 | — | — | US | claimed |
| US-7074782-B2 | Carbamate caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-07-11 | — | — | US | claimed |
| US-20040053920-A1 | Carbamate caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2004-03-18 | — | — | US | claimed |
| EP-1392289-A2 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2004-03-03 | — | — | EP | claimed |
| US-20030092703-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-05-15 | — | — | US | claimed |
| EP-1268425-A2 | CARBAMATE CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2003-01-02 | — | — | EP | claimed |
| WO-2002094263-A2 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-11-28 | — | — | WO | claimed |
| US-20020028803-A1 | Carbamate caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2002-03-07 | — | — | US | claimed |
| WO-2001072707-A2 | CARBAMATE CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-10-04 | — | — | WO | claimed |
| EP-0197829-A1 | 5H-pyrido[3',4':4,5]pyrrolo[3,2-c]pyridine derivatives, process for their preparation and their antitunour activity | SANOFI (FR) | 1986-10-15 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028803-A1 | Carbamate caspase inhibitors and uses thereof | CASP1, CASP2, CASP3 | ACHE 866/4885PARP1 1630/4885KIF11 4836/4885 |
| US-20070155718-A1 | Caspase inhibitor prodrugs | CASP1, CASP5, CASP2 | ACHE 1017/4885PARP1 252/4885KIF11 4772/4885 |
| US-20080015172-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP2, CASP9 | ACHE 3057/4885PARP1 1751/4885KIF11 4845/4885 |
| US-20110144074-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP2, CASP9 | ACHE 3179/4885PARP1 1806/4885KIF11 4873/4885 |
| US-20040053920-A1 | Carbamate caspase inhibitors and uses thereof | CASP1, CASP2, CASP3 | ACHE 866/4885PARP1 1630/4885KIF11 4836/4885 |
| US-20090215736-A1 | CASPASE INHIBITORS AND USES THEREOF | CASP1, CASP2, CASP9 | ACHE 3179/4885PARP1 1806/4885KIF11 4873/4885 |
| US-20030092703-A1 | Caspase inhibitors and uses thereof | CASP1, CASP2, CASP3 | ACHE 3635/4885PARP1 585/4885KIF11 4852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.